EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status

Muhammad Shahzeb Khan, Javed Butler, Rebecca Young, Basil S Lewis, Jorge Escobedo, Jens Refsgaard, Eugene Reyes, Lothar Roessig, Robert O Blaustein, Carolyn S P Lam, Adriaan A Voors, Piotr Ponikowski und 3 weitere

JACC: Heart Failure · 2024

DOI: 10.1016/j.jchf.2024.05.007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Muhammad Shahzeb Khan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Type 2, Pyrimidines, Stroke Volume. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Bayer AG, Merck & Co Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Type 2 diabetes mellitus (T2DM) significantly worsens heart failure (HF) prognosis. OBJECTIVES: This study sought to investigate the impact of T2DM on outcomes in patients enrolled in VICTORIA and assess the efficacy of vericiguat in patients with and without T2DM. METHODS: Patients with HF with reduced ejection fraction were randomized to receive vericiguat or placebo in addition to standard therapy. The primary outcome was a composite of cardiovascular death or first heart failure hospitalization (HFH). A Cox proportional hazards model was used to calculate HRs and 95% CIs to assess if the effect of vericiguat differed by history of T2DM. RESULTS: Of 5,050 patients enrolled, 3,683 (72.9%) had glycosylated hemoglobin (HbA1c) measured at baseline. Of these, 2,270 (61.6%) had T2DM, 741 (20.1%) had pre-T2DM, 449 (12.2%) did not have T2DM, and 178 (4.8%) had undiagnosed T2DM. The risks of the primary outcome, HFH, and all-cause and cardiovascular mortality were high across all categories. The efficacy of vericiguat on the primary outcome did not differ in patients stratified by T2DM by history (HR: 0.92; 95% CI: 0.81-1.04), T2DM measured by HbA1c (HR: 0.77; 95% CI: 0.49-1.20), and pre-T2DM measured by HbA1c (HR: 0.88; 95% CI: 0.68-1.13) and in those with normoglycemia (HR: 1.02: 95% CI: 0.75-1.39; P for interaction = 0.752). No significant differences were observed in subgroups with respect to the efficacy of vericiguat on HFH and all-cause or cardiovascular death. CONCLUSIONS: In this post hoc analysis of VICTORIA, vericiguat compared with placebo significantly reduced the risk of cardiovascular death or HFH in patients with worsening HF with reduced ejection fraction regardless of T2DM status. (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction [HFrEF] [Mk-1242-001] [VICTORIA]; NCT02861534).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureDiabetes Mellitus, Type 2PyrimidinesStroke VolumeHumansMaleFemaleAgedMiddle AgedGlycated HemoglobinHospitalizationDouble-Blind MethodTreatment OutcomeProportional Hazards ModelsHeterocyclic Compounds, 2-Ring

Stichwörter der Autor:innen

diabetesheart failure with reduced ejection fractionvericiguat

Substanzen

vericiguatPyrimidinesGlycated HemoglobinHeterocyclic Compounds, 2-Ring

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Baylor University Medical Center, Dallas, Texas, USA.
  • Lady Davis Carmel Medical Center, Haifa, Israel.
  • National Autonomous University of Mexico, Mexico City, Mexico.
  • Regional Hospital Viborg, Viborg, Denmark.
  • Philippine General Hospital, Manila, Philippines.

Förderung

  • Bayer AG
  • Merck & Co Inc

Zitieren

APA

Khan, M. S., Butler, J., Young, R., Lewis, B. S., Escobedo, J., Refsgaard, J., Reyes, E., Roessig, L., Blaustein, R. O., Lam, C. S. P., Voors, A. A., Ponikowski, P., Anstrom, K. J., Armstrong, P. W., & VICTORIA Study Group (2024). Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.05.007

Vancouver

Khan MS, Butler J, Young R, Lewis BS, Escobedo J, Refsgaard J, et al. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2024.05.007

BibTeX
@article{Khan2024,
  author = {Khan, Muhammad Shahzeb and Butler, Javed and Young, Rebecca and Lewis, Basil S and Escobedo, Jorge and Refsgaard, Jens and Reyes, Eugene and Roessig, Lothar and Blaustein, Robert O and Lam, Carolyn S P and Voors, Adriaan A and Ponikowski, Piotr and Anstrom, Kevin J and Armstrong, Paul W and VICTORIA Study Group, VICTORIA Study Group},
  title = {Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status},
  journal = {JACC: Heart Failure},
  year = {2024},
  doi = {10.1016/j.jchf.2024.05.007}
}
Kostenlos starten →